PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Early Long-Acting Injectables in Schizophrenia: A Manufacturer-Funded Narrative Case

long-acting injectable antipsychoticspaliperidone palmitaterisperidone LAIaripiprazoleschizophreniaearly phase psychosismedication adherencerelapse preventionnarrative reviewdeprescribingambulatory care Psychiatry / Psychopharmacology

Background Information

Early LAI use in schizophrenia improves outcomes and adherence.

Early intervention with long-acting injectable (LAI) antipsychotics in schizophrenia could improve outcomes significantly. LAIs used early in treatment show reduced relapse rates and lower healthcare costs. Encourages first-line use of LAIs, yet notes current underuse and need for improved clinical adoption. Consider LAIs early in schizophrenia for better adherence and outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Harrison SJ, Antunes J, Knight K, Johnston K, Mehawej J, Sanchez P, Correll CU

Citation: Harrison SJ, Antunes J, Knight K, et al. The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia. CNS drugs. 2026;40(7):921-948. doi:10.1007/s40263-026-01294-9

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.